Agilent Technologies, which recently completed its acquisition of BIOVECTRA, is undergoing a major organizational overhaul to drive growth and better serve its customers. The new structure, effective immediately, divides the company into three business groups focused on specific end markets:
 

• Life Sciences and Diagnostics Markets Group (LDG): Targeting pharma, biopharma, clinical, and diagnostics markets.
• Applied Markets Group (AMG): Focusing on food, environmental, forensics, chemicals, and advanced materials markets.
• Agilent CrossLab Group (ACG): Supporting customers across all end markets with services, software, automation, and consumables.

 
This restructuring aims to streamline operations, enhance collaboration, and accelerate market-focused solutions. Key leadership appointments include Simon May as president of LDG, Mike Zhang as president of AMG, and Angelica Riemann continuing as president of ACG.
 
Agilent will share additional details about the company’s market-focused, customer-first enterprise strategy and transformation at its Analyst and Investor Day on Dec. 17, 2024.